Immunovaccine, Merck deal

Immunovaccine and Merck partnered to evaluate Immunovaccine’s DPX-Survivac in combination with Merck’s cancer drug Keytruda pembrolizumab plus low-dose cyclophosphamide in an open-label Phase II trial to treat advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in about 42 patients. Merck will fund the trial, which the Princess Margaret Cancer Center will conduct. ...